Efficacy and Safety of Neoadjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Mengfei Sun's study integrates a network meta-analysis of clinical trials with a real-world cohort of 113 patients from the National Cancer Centre of China (January 2021–December 2023). The analysis compares pathological response rates and adverse events for different neoadjuvant immunotherapy combinations in locally advanced resectable esophageal squamous cell carcinoma. It was last updated on March 18, 2026.

Use Cases

• Compare pathological complete response (pCR) rates across different neoadjuvant immunotherapy regimens based on the network meta-analysis results.
• Assess the association between major pathological response (MPR) and long-term survival outcomes based on the multivariate analysis findings.
• Evaluate the safety profiles of different regimens by comparing adverse event (AE) incidence rates mentioned in the results.
• Investigate the impact of neoadjuvant radiotherapy on overall and progression-free survival based on the real-world study's regression analysis.

Strengths

• Integrates evidence from a systematic network meta-analysis with a real-world cohort of 113 patients.
• Provides specific comparative efficacy metrics, such as a 46.9% vs. 12.5% MPR rate for Camrelizumab vs. Tislelizumab groups.
• Includes a PROSPERO systematic review registration (CRD420251174359) for transparency.

Limitations

• The underlying data is a 341.6 KB DOCX file; the actual structured data tables, column definitions, and row counts are not provided.
• The real-world cohort is from a single center in China, which may limit generalizability to other populations.
• Column-level documentation is absent; field semantics must be inferred from the manuscript text after download.

Provenance

Source

Author: Mengfei Sun. Organization: unknown.

Collection Method

Systematic review and network meta-analysis of RCTs and cohort studies, combined with a retrospective analysis of patient records.

Time Range

Real-world patient data covers January 2021 to December 2023.

Freshness

Last updated 2026-03-18 07:36:04.

Geography

Real-world cohort is from the National Cancer Centre of China.